Brightening Agent

Tranexamic Acid

Tranexamic acid inhibits melanin production by blocking the plasminogen-to-plasmin conversion that activates melanocytes. It has growing RCT evidence for melasma treatment (both oral and topical) and is well tolerated with minimal irritation.

topicalpigmentationbrighteningmelasma

Moderate Evidence

Last reviewed: March 2026 · Our methodology

What It Does

Tranexamic acid (TXA) is a synthetic analogue of lysine originally developed as an anti-fibrinolytic agent to control bleeding. Its dermatological application was discovered incidentally when patients receiving oral TXA for bleeding disorders noticed improved melasma.

The mechanism in skin: UV radiation and inflammation activate plasmin in keratinocytes, which triggers melanocyte-stimulating pathways. Tranexamic acid blocks the conversion of plasminogen to plasmin, interrupting this signalling cascade. This makes it effective for UV-triggered and inflammation-driven pigmentation — particularly melasma, which is notoriously difficult to treat.

Unlike hydroquinone (which directly inhibits tyrosinase), TXA works upstream in the melanin production pathway, which may explain why it is effective for types of pigmentation that respond poorly to conventional brightening agents.

Best Use Cases

Melasma (the most promising non-hydroquinone option)
Post-inflammatory hyperpigmentation
UV-induced pigmentation and sun spots
Stubborn pigmentation that has not responded to vitamin C or azelaic acid alone

Who May Benefit Most

People with melasma or stubborn pigmentation, those who have tried hydroquinone and experienced irritation or rebound, and anyone seeking a well-tolerated brightening agent that works through a different mechanism than most alternatives.

Cautions

Topical tranexamic acid (2–5%) is generally well tolerated with minimal irritation. Oral tranexamic acid (250mg twice daily, used in some melasma studies) has higher systemic risk — it should only be used under medical supervision due to theoretical thrombotic risk, especially in those with clotting disorders, on oral contraceptives, or with a history of blood clots. Topical use does not carry these systemic risks.

Common Mistakes

Confusing topical and oral TXA safety profiles — topical is very safe; oral requires medical supervision
Expecting monotherapy to resolve melasma — TXA works best in combination with other agents
Not using sunscreen consistently (essential for any pigmentation treatment)
Giving up too early — pigmentation changes take 8–16+ weeks

Combines Well With

Niacinamide (complementary pigmentation pathways)
Vitamin C (different mechanism — antioxidant vs plasmin inhibition)
Azelaic acid (tyrosinase inhibition + anti-inflammatory)
Sunscreen (absolutely essential)
Alpha arbutin (tyrosinase inhibition via different mechanism)

May Combine Poorly With

No known significant topical incompatibilities — TXA is notable for its compatibility

Realistic Timeline

Some studies show improvement at 4–8 weeks. Meaningful melasma improvement typically requires 12–24 weeks of consistent use. As with all pigmentation treatments, results are maintenance-dependent — stopping treatment often leads to gradual return of pigmentation, especially without rigorous sun protection.

Disclaimer

Topical tranexamic acid is available OTC in many skincare products. Oral tranexamic acid for melasma is a medical treatment that requires prescription and monitoring. Consult a dermatologist for melasma management, especially if considering oral formulations.